vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Liberty Broadband Corp (LBRDA). Click either name above to swap in a different company.

Liberty Broadband Corp is the larger business by last-quarter revenue ($261.0M vs $196.0M, roughly 1.3× Axsome Therapeutics, Inc.). Liberty Broadband Corp runs the higher net margin — 146.7% vs -14.6%, a 161.3% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 6.1%). Liberty Broadband Corp produced more free cash flow last quarter ($37.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 4.3%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Liberty Global Ltd. is a British-Dutch-American multinational telecommunications company domiciled in Bermuda, with headquarters in London, Amsterdam and Denver. Its respective legal names are Liberty Global Holdings Limited (UK), Liberty Global B.V. (Netherlands) and Liberty Global, Inc., with the first of these being publicly traded. It was formed in 2005 by the merger of the international arm of Liberty Media and UnitedGlobalCom (UGC).

AXSM vs LBRDA — Head-to-Head

Bigger by revenue
LBRDA
LBRDA
1.3× larger
LBRDA
$261.0M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+58.9% gap
AXSM
65.0%
6.1%
LBRDA
Higher net margin
LBRDA
LBRDA
161.3% more per $
LBRDA
146.7%
-14.6%
AXSM
More free cash flow
LBRDA
LBRDA
$55.7M more FCF
LBRDA
$37.0M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
4.3%
LBRDA

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
AXSM
AXSM
LBRDA
LBRDA
Revenue
$196.0M
$261.0M
Net Profit
$-28.6M
$383.0M
Gross Margin
Operating Margin
-13.8%
15.7%
Net Margin
-14.6%
146.7%
Revenue YoY
65.0%
6.1%
Net Profit YoY
61.9%
96.4%
EPS (diluted)
$-0.55
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
LBRDA
LBRDA
Q4 25
$196.0M
Q3 25
$171.0M
Q2 25
$150.0M
$261.0M
Q1 25
$121.5M
$266.0M
Q4 24
$118.8M
$263.0M
Q3 24
$104.8M
$262.0M
Q2 24
$87.2M
$246.0M
Q1 24
$75.0M
$245.0M
Net Profit
AXSM
AXSM
LBRDA
LBRDA
Q4 25
$-28.6M
Q3 25
$-47.2M
Q2 25
$-48.0M
$383.0M
Q1 25
$-59.4M
$268.0M
Q4 24
$-74.9M
$291.0M
Q3 24
$-64.6M
$142.0M
Q2 24
$-79.3M
$195.0M
Q1 24
$-68.4M
$241.0M
Operating Margin
AXSM
AXSM
LBRDA
LBRDA
Q4 25
-13.8%
Q3 25
-27.0%
Q2 25
-24.5%
15.7%
Q1 25
-46.9%
16.2%
Q4 24
-61.1%
4.9%
Q3 24
-59.8%
11.5%
Q2 24
-89.5%
8.5%
Q1 24
-89.7%
11.4%
Net Margin
AXSM
AXSM
LBRDA
LBRDA
Q4 25
-14.6%
Q3 25
-27.6%
Q2 25
-32.0%
146.7%
Q1 25
-48.9%
100.8%
Q4 24
-63.1%
110.6%
Q3 24
-61.7%
54.2%
Q2 24
-91.0%
79.3%
Q1 24
-91.1%
98.4%
EPS (diluted)
AXSM
AXSM
LBRDA
LBRDA
Q4 25
$-0.55
Q3 25
$-0.94
Q2 25
$-0.97
$2.68
Q1 25
$-1.22
$1.87
Q4 24
$-1.54
$2.04
Q3 24
$-1.34
$0.99
Q2 24
$-1.67
$1.36
Q1 24
$-1.44
$1.69

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
LBRDA
LBRDA
Cash + ST InvestmentsLiquidity on hand
$322.9M
$180.0M
Total DebtLower is stronger
$3.1B
Stockholders' EquityBook value
$88.3M
$10.4B
Total Assets
$689.8M
$16.6B
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
LBRDA
LBRDA
Q4 25
$322.9M
Q3 25
$325.3M
Q2 25
$303.0M
$180.0M
Q1 25
$300.9M
$226.0M
Q4 24
$315.4M
$163.0M
Q3 24
$327.3M
$168.0M
Q2 24
$315.7M
$73.0M
Q1 24
$331.4M
$108.0M
Total Debt
AXSM
AXSM
LBRDA
LBRDA
Q4 25
Q3 25
Q2 25
$3.1B
Q1 25
$3.8B
Q4 24
$3.8B
Q3 24
$3.7B
Q2 24
$3.6B
Q1 24
$3.6B
Stockholders' Equity
AXSM
AXSM
LBRDA
LBRDA
Q4 25
$88.3M
Q3 25
$73.7M
Q2 25
$73.1M
$10.4B
Q1 25
$53.2M
$10.1B
Q4 24
$57.0M
$9.8B
Q3 24
$92.9M
$9.5B
Q2 24
$102.9M
$9.3B
Q1 24
$144.0M
$9.1B
Total Assets
AXSM
AXSM
LBRDA
LBRDA
Q4 25
$689.8M
Q3 25
$669.3M
Q2 25
$639.8M
$16.6B
Q1 25
$596.7M
$17.0B
Q4 24
$568.5M
$16.7B
Q3 24
$561.5M
$16.3B
Q2 24
$548.2M
$16.0B
Q1 24
$545.7M
$15.7B
Debt / Equity
AXSM
AXSM
LBRDA
LBRDA
Q4 25
Q3 25
Q2 25
0.30×
Q1 25
0.38×
Q4 24
0.38×
Q3 24
0.39×
Q2 24
0.39×
Q1 24
0.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
LBRDA
LBRDA
Operating Cash FlowLast quarter
$-18.7M
$91.0M
Free Cash FlowOCF − Capex
$-18.7M
$37.0M
FCF MarginFCF / Revenue
-9.6%
14.2%
Capex IntensityCapex / Revenue
0.0%
20.7%
Cash ConversionOCF / Net Profit
0.24×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$-49.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
LBRDA
LBRDA
Q4 25
$-18.7M
Q3 25
$1.0M
Q2 25
$-32.4M
$91.0M
Q1 25
$-43.4M
$78.0M
Q4 24
$-26.2M
$1.0M
Q3 24
$-18.6M
$24.0M
Q2 24
$-30.1M
$27.0M
Q1 24
$-53.5M
$52.0M
Free Cash Flow
AXSM
AXSM
LBRDA
LBRDA
Q4 25
$-18.7M
Q3 25
$988.0K
Q2 25
$-32.4M
$37.0M
Q1 25
$-43.7M
$13.0M
Q4 24
$-26.2M
$-63.0M
Q3 24
$-18.7M
$-36.0M
Q2 24
$-30.2M
$-35.0M
Q1 24
$-53.6M
$-9.0M
FCF Margin
AXSM
AXSM
LBRDA
LBRDA
Q4 25
-9.6%
Q3 25
0.6%
Q2 25
-21.6%
14.2%
Q1 25
-36.0%
4.9%
Q4 24
-22.1%
-24.0%
Q3 24
-17.9%
-13.7%
Q2 24
-34.6%
-14.2%
Q1 24
-71.4%
-3.7%
Capex Intensity
AXSM
AXSM
LBRDA
LBRDA
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
20.7%
Q1 25
0.3%
24.4%
Q4 24
0.0%
24.3%
Q3 24
0.1%
22.9%
Q2 24
0.1%
25.2%
Q1 24
0.1%
24.9%
Cash Conversion
AXSM
AXSM
LBRDA
LBRDA
Q4 25
Q3 25
Q2 25
0.24×
Q1 25
0.29×
Q4 24
0.00×
Q3 24
0.17×
Q2 24
0.14×
Q1 24
0.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons